HSI Donesafe & Neopharmas Announce Partnership

HSI Donesafe and Neopharmas announce strategic partnership to strengthen workplace impairment management

HSI Donesafe, a global provider of health, safety and environment (HSE) software, has announced a new technical referral partnership with Neopharmas, a specialist in drug, alcohol and impairment testing solutions.

The partnership brings together two complementary areas of workplace safety. HSI Donesafe’s safety management platform provides the structure and oversight organisations need, while Neopharmas delivers the specialist testing capabilities required to identify and manage impairment risks on site. Together, they offer a more complete, practical approach to impairment management for high-risk industries.

Addressing a critical compliance gap

In high-risk environments, impairment caused by drugs, alcohol, fatigue or prescription medication remains one of the most serious threats to worker safety. While many organisations have safety systems in place, impairment is often managed separately, creating gaps in visibility, reporting and accountability.

Through this partnership, testing outcomes can be more effectively connected to broader safety workflows, helping organisations move beyond isolated checks and towards a more integrated, preventative approach.

“By working with Neopharmas, we’re helping our customers manage impairment risks in a way that is both practical and defensible,” said Louise Minty, Partnerships Manager from HSI Donesafe. “We’re focused on reducing the real risks that lead to serious incidents.”

The cost of getting it wrong

Australian WHS legislation treats impairment risks with the same seriousness as any other critical safety hazard. Organisations have a duty to provide safe systems of work and to monitor worker health where risks are present.

Penalties for non-compliance are significant. Under the WHS Act, Category 1 (reckless conduct) offences carry maximum penalties of:

• Corporations: up to $10.425 million
• Officers and individuals: up to $2.085 million and up to 10 years’ imprisonment

Even where no incident occurs, a Category 2 breach — such as failing to have systems in place to manage drug and alcohol risks — can result in fines of up to $1.5 million for a body corporate.

A practical, joined-up approach

The HSI Donesafe and Neopharmas partnership supports PCBUs in meeting their obligations by helping them to:

• Proactively identify and reduce impairment risks through structured testing
• Integrate testing outcomes into safety reporting and workflows
• Monitor worker health and workplace conditions more effectively
• Support officers in meeting their due diligence requirements

By combining strong governance and reporting with specialist testing expertise, organisations in high-risk sectors can take a more confident, defensible approach to keeping workers safe and fit for work.

About HSI Donesafe

HSI Donesafe is a market-leading safety management software platform that connects safety, compliance and risk management in one system. Donesafe helps teams manage complex safety requirements in a clear, practical way.

About Neopharmas

Neopharmas provides specialist drug, alcohol and impairment testing solutions for high-risk industries. Its services help organisations identify and manage impairment risks before they lead to serious harm. Learn more about Neopharmas here: https://www.neopharmatechnologies.com/